ASCO Annual Meeting | Conference

Dr. Yao on Health-Related QOL in Patients With Neuroendocrine Tumors

September 28th 2016

James C. Yao, MD, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, discusses a study exploring health-related quality of life (QOL) in patients with neuroendocrine tumors (NETs).

Dr. Idos on Remaining Questions With Multiplex Panel Testing

September 28th 2016

Gregory E. Idos, MD, assistant professor of Clinical Medicine, Department of Surgery, Division of Colorectal Surgery, Keck School of Medicine of University of Southern California, sheds light on the remaining questions with multiplex panel testing as well as the cost effectiveness of it.

Next-Generation Sequencing Analysis of Circulating Tumor DNA

September 26th 2016

Oliver Zill, data scientist, Guardant Health, discusses the somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA.

Dr. Mehnert on Promising Biomarkers for Immunotherapy

September 26th 2016

Janice Mehnert, MD, medical oncologist, director, Phase I and Developmental Therapeutics Program, Rutgers Cancer Institute of New Jersey, discussing promising biomarkers for patients to receive immunotherapy across tumor types.

Dr. Strosberg on the Results of the NETTER-1 Trial

September 8th 2016

Jonathan Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the results of the NETTER-1 trial.

Dr. Donnellan on TFR in Patients With CML Treated With Nilotinib

September 7th 2016

William B. Donnellan, MD, investigator, Hematologic Malignancies, principal investigator, Sarah Cannon Research Institute, discusses preliminary results of the ENESTop study, which looked at treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase who were treated with second-line nilotinib (Tasigna).

Benefit of Maintenance Olaparib in Patients With Ovarian Cancer

August 25th 2016

Charlie Gourley, PhD, MBChB, chair and honorary consultant in Medical Oncology at Edinburgh Cancer Research Centre in the United Kingdom, discusses a study comparing the use of olaparib (Lynparza) after chemotherapy with placebo after chemotherapy in patients with platinum-sensitive ovarian cancer.

Dr. Gadgeel on Pembrolizumab/Chemo Combo in NSCLC

August 23rd 2016

Shirish Gadgeel, MD, medical oncologist, leader of the Thoracic Oncology Multidisciplinary Team at Karmanos Cancer Institute, Wayne State University, discusses the KEYNOTE-021 study, which is examining the combination of pembrolizumab (Keytruda) and chemotherapy as a potential treatment for patients with non–small cell lung cancer.

Early Promise of Radiation Plus PCV in Patients With Low-Grade Glioma

August 19th 2016

Erica Bell, PhD, assistant professor-Clinical, Ohio State University Comprehensive Cancer Center, discusses a mutational analysis examining radiation therapy plus procarbazine, CCNU, and vincristine (PCV) as a potential treatment for patients with high-risk, low-grade glioma.

Dr. Rudin on Rova-T in Patients With Small Cell Lung Cancer

August 18th 2016

Charles M. Rudin, MD, medical oncologist, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses the safety and efficacy of single-agent rovalpituzumab tesirine (Rova-T) in patients with recurrent or refractory small cell lung cancer (SCLC).

Dr. Leslie Randall Discusses Evidence Supporting BRCA Testing in Ovarian Cancer

August 10th 2016

Leslie M. Randall, MD, associate professor of Gynecology/ Oncology, University of California Irvine, discusses evidence supporting the use of BRCA testing for patients with ovarian cancer.

Dr. West on Advancements for Patients With T790M-Mutant NSCLC

August 8th 2016

Howard L. (Jack) West, MD, medical oncologist, director, Thoracic Oncology Program, Swedish Cancer Institute, discusses recent advancements for patients with T790M-mutant non–small cell lung cancer.

Dr. Harold J. Burstein on CDK4/CDK6 Inhibitor Abemaciclib in Breast Cancer

August 7th 2016

​Harold J. Burstein, MD, PhD, Senior Physician, Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute discusses the results of MONARCH1, which looked at abemaciclib as monotherapy in patients with ER-positive breast cancer, after chemotherapy for advanced disease.

Dr. Robert Coleman on the Importance of BRCA Testing in Ovarian Cancer

August 4th 2016

Robert Coleman, MD a professor in the Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, discusses the importance of BRCA testing for patients diagnosed with ovarian cancer.

Dr. Keith T. Flaherty on 3-Year Follow-up of COMBI-d in Metastatic Melanoma

August 2nd 2016

Challenges With a Precision Medicine-Based Approach in Oncology

August 1st 2016

Holli Dilks, PhD, director, Personalized Medicine Operations, Sarah Cannon Research Institute, discusses the challenges associated with having a precision medicine-based approach in the field of oncology.

Dr. Topalian on Evolution of PD-1/PD-L1 Agents in Oncology

August 1st 2016

Suzanne L. Topalian, MD, director, Melanoma Program, professor of Surgery, Johns Hopkins Medicine, discusses how the use of PD-1/PD-L1 inhibitors in multiple tumor types has dramatically evolved over the last 4 years.

Dr. Falchook on KTN3379 in Advanced Tumors

July 29th 2016

Gerald S. Falchook, MD, director, Drug Development, Sarah Cannon Research Institute, discusses a phase Ib study examining the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of the anti-ErbB3 agent KTN3379 in adults with advanced tumors. The agent was studied alone and with targeted therapies.

Dr. El-Jawahri on Early Integrated Palliative Care in Patients With Lung or GI Cancer

July 29th 2016

Areej R. El-Jawahri, MD, assistant in Medicine, Massachusetts General Hospital, instructor in Medicine, Harvard Medical School, discusses a study examining early integrated palliative care for patients with gastrointestinal (GI) or lung cancer and the impact it has on family caregiver outcomes.

Impact of Precision Medicine in Refractory Malignancies

July 28th 2016

Maria Schwaederle, PharmD, Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California, San Diego, discusses results of a meta-analysis of 13,203 patients in phase I clinical trials.